Please read all below – then go back and read Naw, they wouldn’t do that…
Yesterday I had a conversation with a woman I know, a Nurse Practitioner at a large, prestigious medical facility in Seattle.
Question: Do you have ANY information on vaccine for Ebola? The only information I have is availability possibly at the end of year. I am asking because we are sending 3000 troops to W. Africa to aid….
Answer: I haven’t heard anything in the medical community about a vaccine. There is a non-FDA-approved treatment that was used on the two Americans who were infected recently but that is all that I have heard of. Transmission of the Ebola virus, all-crazy-infectious-diseases-considered, can be effectively prevented with proper precautions.
Question: OK, thank you. My understanding of it too (prevented w/proper precautions) however the push is on to develop vaccine. If you hear/see anything….
Richard/Hyscience is far more knowledgeable on this subject than I and I hope we hear from him soon.
The first human trial for an investigational Ebola vaccine is set to begin this week.The ongoing Ebola outbreak in West Africa prompted the National Institutes of Health to expedite safety testing for several vaccines already in the works. Since March, the deadly virus has killed 1,552 people, according to the World Health Organization, which predicted last week that the virus could infect 20,000 people in the next six months.
An Ebola vaccine is different from the experimental Ebola drug ZMapp, which two Americans received last month and is designed to treat an existing Ebola infection rather than prevent one.
“There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said in a statement.
The NIH is developing the vaccine with pharmaceutical giant GlaxoSmithKline. Although Fauci said the vaccine has “performed extremely well” in primate studies, it has not yet been tested in humans.
The phase 1 clinical trial set to begin this week at the NIH Clinical Center in Bethesda, Maryland, will involve 20 human subjects between the ages of 18 and 50, according to the NIH.
Researchers will use the study to determine whether the vaccine is safe and see whether it prompts an immune response necessary to protect against Ebola. No human subjects will be infected with Ebola.
A $4.7 million grant will also go toward Ebola vaccine trials in September at the University of Oxford in England, as well as centers in Gambia and Mali, according to GlaxoSmithKline. In all, 140 patients will be tested.
Though Ebola was discovered nearly 40 years ago, it was so rare that drug manufacturers weren’t interested in investing in finding a vaccine for it, said Dr. William Schaffner, chair of preventive medicine at Vanderbilt University in Nashville, Tennessee. Its rarity also made it impossible for scientists to conduct field studies.
“There’s always the layperson’s query of ‘Why don’t they rush this?’ ‘Why don’t these guys work a little later at night?'” Schaffner told ABC News in July. “It’s a little more complicated than that.”
GlaxoSmithKline became involved in the Ebola vaccine because it bought Swiss vaccine company Okairos AG in 2013. Okairos, originally a Merck spinoff, had been working on the vaccine with the NIH since 2011, a GlaxoSmithKline spokeswoman told ABC News.
Although Fauci said in July that it would take until late 2015 for a vaccine — if successful — to be administered to a limited number of health workers, GlaxoSmithKline said in a statement that the grant will also enable it to manufacture 10,000 doses of the vaccine while the trials are ongoing. If the vaccine trials are successful, it will be able to make stocks available immediately to the World Health Organization.
The NIH said it should have initial data from the trial in late 2014.
The trial for different vaccine is set to begin at the Walter Reed Army Institute of Research in Silver Spring, Maryland. This vaccine was a collaboration between the federal Department of Defense and Iowa pharmaceutical company NewLink Genetics Corp.
The Clinical Center Building, where the testing on humans with an experimental vaccine to prevent the Ebola virus has begun, at the National Institutes of Health (NIH) in Bethesda, Md. (European Pressphoto Agency/Michael Reynolds)
The first human trial of an Ebola vaccine has so far produced no adverse effects, according to a National Institutes of Health official.
The comments were made by Anthony Fauci, director of the NIH’s Institute of Allergy and Infe
ctious Diseases when he testified before Congress on the Ebola virus epidemic in West Africa on Tuesday.
“So far 10 of the 20 volunteers have been vaccinated, and thus far there have been no red flags,” Fauci said.
The Phase I trial is being conducted at an NIH facility in Bethesda, Md. and is focused on building scientific evidence that the vaccine is safe in humans. It was developed by British drug-maker GlaxoSmithKline in conjunction with the NIH.
The vaccine is based on a chimpanzee cold virus, chimp adenovirus type 3, which is being used as a carrier of pieces of genetic material of two Ebola strains: Sudan and Zaire; the latter is currently causing the massive epidemic in West Africa. The Ebola genetic material in the virus is not able to replicate and poses no harm to the people who receive it.
This process is just the first phase of a multi-step evaluation intended to show that the virus is safe, and that it works in humans. Facui said that this first phase of clinical trials for the vaccine is expected to finish by the end of November or early December. After that, they will launch expanded trials to further prove that the vaccine is safe.
“The proof is in the pudding to show scientifically that it works,” Fauci said.